碳酸锂缓释片治疗双相情感障碍的躁狂发作的疗效探讨  

Effect of lithium carbonate sustained release tablets on manic episode of bipolar disorder

作　　者：周绍宇[1] 靳西龙[3] 冯振晓 赵丽华[2] Zhou Shaoyu;Jin Xilong;Feng Zhenxiao;Zhao Lihua(Third Ward,Jinshan District Mental Health Center,Shanghai 201508,China)

机构地区：[1]上海市金山区精神卫生中心临床三病区,201508 [2]上海市金山区精神卫生中心临床四病区,201508 [3]浙江省湖州市第三人民医院临床五病区

出　　处：《中国药物与临床》2019年第19期3282-3285,共4页Chinese Remedies & Clinics

摘　　要：目的探究利培酮与碳酸锂缓释片联合治疗双相情感障碍躁狂发作的临床效果。方法将从2015年6月至2018年6月我院收治的双相情感障碍的躁狂发作患者根据治疗方法的不同分为对照组和试验组;对照组(39例)实施利培酮治疗,试验组(40例)实施利培酮联合碳酸锂缓释片治疗;对比分析2组患者Bech-Rafaelsen躁狂评估量表(BRMS)评分、认知功能以及不良反应。结果在治疗前2组患者BRMS、威斯康星卡片分类测验法(WCST)、持续操作测验评估量表(CPT)以及言语记忆测验评估量表(HVLT-R)评分差异无统计学意义(P>0.05)。在治疗1、2、4、8周后,2组患者BRMS评分均显著低于治疗前(P<0.05);其中试验组在治疗1、2、4、8周后BRMS评分分别为(15.5±1.8)分、(11.2±1.8)分、(9.2±1.8)分、(5.5±1.5)分,均显著低于对照组(P<0.05)。治疗后,2组患者WCST和HVLT-R评分相比于治疗前差异无统计学意义(P>0.05),2组患者CPT评分均显著高于治疗前(P<0.05),试验组(3.7±0.6)分显著高于对照组(2.8±0.6)分(P<0.05)。2组患者在不良反应发生率上差异无统计学意义(P>0.05);但试验组患者在心跳过快(10%)、多饮(12%)、恶心呕吐(10%)和无力嗜睡(12.50%)等不良反应发生率上均高于对照组。结论利培酮与碳酸锂缓释片联合治疗双相情感障碍的躁狂发作患者可降低BRMS评分,可提升患者注意力,不会增加患者的不良反应,对临床用药具有一定的指导意义。Objective To investigate the clinical effect of risperidone and lithium carbonate sustained release tablets in the treatment of manic episode of bipolar disorder.Methods The bipolar disorder patients with manic episode admitted to our hospital between June 2015 and June 2018 were divided into the control group and study group according to different treatment methods.The control group(n=39)was treated with Risperidone,and the study group(n=40)was treated with risperidone and lithium carbonate sustained release tablets.The BRMS score,cognitive function and adverse reactions were compared between the two groups.Results There were no significant differences in BRMS,WCST,CPT and HVLT-R scores between the two groups at baseline(all P>0.05).At 1,2,4 and 8 weeks after the treatment,the BRMS scores in both groups were significantly lower than baseline(all P<0.05).The BRMS score in the study group at 1,2,4 and 8 weeks after the treatment was(15.5±1.8),(11.2±1.8),(9.2±1.8)and(5.5±1.5),respectively,which was significantly lower than those in the control group(P<0.05).After the treatment,there were no significant differences in WCST and HVLT-R scores between the two groups(both P>0.05).The CPT score in both groups was significantly higher than baseline(P<0.05),and was significantly higher in the study group than that in the control group[(3.7±0.6)vs(2.8±0.6),P<0.05].There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).However,the incidence of adverse reactions such as tachycardia(10%),polydipsia(12%),nausea and vomiting(10%),and weakness and drowsiness(12%)in the study group was more frequent compared with the control group.Conclusion The combination of risperidone and lithium carbonate sustained release tablets in the treatment of bipolar disorder patients with manic episode may reduce BRMS score and improve the attention of patients,will not increase the adverse reactions.These information should be useful for clinical medication.

关 键 词：双相情感障碍 利培酮 碳酸锂缓释片 BRMS评分 认知水平 

分 类 号：R74[医药卫生—神经病学与精神病学]